Sigma-Aldrich to offer start to finish bio-testing thanks to BioReliance takeover

By Natalie Morrison

- Last updated on GMT

Related tags: Drug discovery, Pharmacology, Contract research organization

Sigma-Aldrich to offer start to finish bio-testing thanks to BioReliance takeover
Sigma-Aldrich says it is a step closer to becoming a one-stop-shop for biopharmas in the drug discovery process after it inked a takeover agreement with biological testing firm BioReliance.

The deal – a $350m (€273m) deal with previous owners Avista Capital Partners – will add new capabilities in biologics testing, specialized toxicology and animal health testing for pharmaceutical and biopharmaceutical diagnostics to Sigma-Aldrich’s portfolio.

BioReliance president and CEO Charles Harwood said the acquisition “creates one of the broadest product and service offerings for the development and manufacture of biological drugs”​.

The contract research organisation’s (CRO) marketing manager Susan Livingston, told Outsourcing-Pharma this will be the first time Sigma-Aldrich has been able to offer QA/QC (quality assurance, and quality testing) services from raw material to completed product.

She said: “I think it will be very beneficial to the industry. Sigma-Aldrich customers in industrial parts of the business are used to dealing with the firm for just their raw materials, and now they have access to services that compliment that.

“It will offer more of a one-stop-shop service to both our existing clients, mainly large pharmas and biotechs, as well as the many clients using Sigma-Aldrich’s services.”

Sigma-Aldrich currently develops, makes and distributes biochemical and organic chemical products and kits used in scientific research, including genomic and proteomic research.

Biologics are the name of the game

Through a renewed focus in biologic drug development, the BioReliance purchase a large factor in this strategy, Sigma-Aldrich now estimates a growth in earnings per share in 2012.

President and CEO of the firm, Rakesh Sachdev, said: “As the market continues its focus on biological drug development, our leadership in this area should enable us to build even better, more customer-specific solutions.

“We are excited to add BioReliance's capabilities and its talented employees to our Company and fully expect its addition to contribute to our long-term growth and return goals."

BioReliance pulled-in $110m in revenues in 2010, predicts higher revenues for its 2011 results. The company has laboratories in Rockville and Scotland, and offices in Japan and India. It employs more than 650 people.


Of changes made at BioReliance under the new deal, Livingston told us the company expects operations to remain largely the same.

As there is very little overlap between services, there is no real reason for change, she said.

She also said that Sigma-Aldrich’s life-sciences analytics company SAFC have “an understanding of our client base so the understand the quality needs of industrial manufacturers of bio-products.”

“Basically, this will extend the reach of SAFC. We fit hand-in-hand and will work mainly with SAFC,” ​she added.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us


View more